Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 inhibitor add-on to basal insulin in type 2 diabetes
NCT03631134Phase 4Unknown
- Sponsor
- Nanjing First Hospital
- Start
- Aug 2018
- Primary completion
- Jan 2019
01
Overview
Phase 4, open-label trial in type 2 diabetes mellitus (T2DM), sponsored by Nanjing First Hospital. Primary endpoint: Changes of glycemic variation at 5 weeks. Status: unknown.
02
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03631134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631134.